Novo Nordisk has launched a shock $9bn (£6.9bn) provide for the US obesity-focused biotech agency Metsera that might gazump an present bid from Pfizer because the pharmaceutical giants battle for dominance within the weight-loss market.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
